ACTH(4-10) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-29. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
== Types == Mummies are typically divided into one of two distinct categories: anthropogenic or spontaneous. Anthropogenic mummies were deliberately created by the living for any number of reasons, the most common being for religious purposes. Spontaneous mummies, such as Ötzi and the Maronite mummies, were created unintentionally due to natural conditions such as extremely dry heat or cold, or acidic and anaerobic conditions such as those found in bogs. While most individual mummies exclusively belong to one category or the other, there are examples of both types being connected to a single culture, such as those from the ancient Egyptian culture and the Andean cultures of South America. Some of the later well-preserved corpses of the mummification were found under Christian churches, such as the mummified vicar Nicolaus Rungius found under the St. Michael Church in Keminmaa, Finland. There are also cases that fall outside of these categories.
=== Suppression tests === Normally, endogenous insulin production is suppressed in the setting of hypoglycemia. A 72-hour fast, usually supervised in a hospital setting, can be done to see if insulin levels fail to suppress, which is a strong indicator of the presence of endogenous hyperinsulinemia, of which the most common cause is insulinoma (followed by autoimmune causes). During the test, the patient may have calorie-free and caffeine-free liquids. Capillary blood glucose is measured every 4 hours using a reflectance meter, until values < 60 mg/dL (3.3 mmol/L) are obtained. Then, the frequency of blood glucose measurement is increased to every hour until values are < 49 mg/dL (2.7 mmol/L). At that point, or when the patient has symptoms of hypoglycemia, a blood test is drawn for serum glucose, insulin, proinsulin, and C-peptide levels. The fast is then stopped at that point, and the hypoglycemia is corrected with intravenous dextrose or carbohydrate-containing food or drink.
== Museum history == The Arabia Steamboat Museum opened on November 13, 1991. Various elements of the museum operated under different corporations: Arabia Instructional Museum Society (1995-2004), Arabia Museum Foundation (founded 1990) and Arabia Salvage Ltd.(founded 1988). The museum and its operations were led by the two brothers who found and excavated the Arabia, Greg and David Hawley, and their parents, Bob and Florence Hawley. Greg was killed by a street racing driver in 2009. Bob died in 2019 and Florence died in 2021. David has continued the operation. The lease in Kansas City (7 miles from the Arabia wreck site) expires in 2026. Plans have been developed to move and expand the Arabia Steamboat Museum. In 2019, it was proposed to build the larger museum and move to Jefferson City, about 140 miles from the site of the Arabia wreck. In 2021, plans were made to create the National Steamboat Museum at Marshall Junction, Missouri, about 77 miles from the site of the wreck. The plans include excavating five additional steamboats so that six are interpreted and displayed at the museum. The Marshall-Saline Development Corporation advance funded a $150,000 feasibility study for the new museum, but is not raising or collecting funds for the museum. On November 13, 2025, the museum announced on their website that they would be closing permanently in November 2026.
=== Development Tools === InSight Development Kits provide the hardware and software tools needed for application development. InSight Desktop allows for the programming and debugging of applications. It combines a packet sniffer, network analysis features, API tracing, and a virtual UART. InSight Adapter is used for network and microprocessor debugging and for programming chips. InSight USB Link is a FLASH programming device that connects to any PC via USB and to Ember’s Radio Control Module (RCM). It contains the hardware and software tools that read and write applications and program FLASH memory on the chips. AppBuilder makes network customization possible. It generates a template application that allows developers to tailor the EmberZNet PRO software to their specifications and complete the application, readying it for hardware integration and testing. It also allows configuration of the Hardware Abstraction Layer (HAL) and generates source code application with places for the developer to insert their own OEM-specific code. xIDE is a tool-chain that supports applications being written for the EM250. It has a C-language compiler, assembler, source-level debugger, and graphical editing environment.
== Career == An outstanding junior excluding one occasion where he was tagged out of the game by Martin Davis (now West Coast Eagles Property manager), Jetta was twice named in the Under 18 All-Australian Team as well as being adjudged the joint winner of the Kevin Sheehan Medal, awarded to the Best Player in Division 1 at the Under 16 National Championships. He was also a graduate of the AIS-AFL Academy in 2005. The speedy forward was drafted by the Bombers with the priority selection (18th overall) in the 2006 AFL draft from South Fremantle. He was drafted as a player renowned for outstanding pace, good foot skill and terrific vision on the ground. He made his AFL debut in the opening round of the 2007 season, along with another of the club's 2006 recruits, Alwyn Davey. Jetta went on to play the following 3 matches before being sidelined by a groin complaint. Despite returning to play with Essendon's VFL affiliate, the Bendigo Bombers, this injury ultimately ended his 2007 season. The 2008 pre-season, saw Jetta return to the club in excellent condition. He equaled the then club record for the 20m sprint with a time of 2.75 seconds, and his skin folds were the lowest they had been. His strong performances in the NAB Cup reflected that increase in fitness. As a result of that good form, Jetta earned selection in Essendon's Round 1 encounter with North Melbourne in which he gathered 13 possessions and showcased his terrific tackling. His good start to the season was interrupted by a hamstring injury sustained in Essendon's round 3 clash with Carlton.
Sources: en.wikipedia.org
"I had the original idea of how the machine would work and it was my patent, but it was a joint effort getting it to work in a saleable form. It was 3 years of very hard work. I had originally studied heavy electrical engineering before changing over to Medical School and qualifying as a Medical Doctor in 1968. In fact I was Senior House (Casualty) Officer (A&E or ER) in 1970 at North Manchester General Hospital when I filed the patent. I must have been the only hospital doctor in Britain with an oscilloscope, a soldering iron and a drawing board in his room in the Doctors' Residence. The housekeepers were bemused by all the wires. Frank originally trained as a Banker but quit to take a job with a local electronics firm during the development. He died in 1987, a terrible loss." [Extract from personal communication received in March 2010 from John Kirby.]
=== Binary, cationic === Group 2 elements form [M(CO)8]+ (M = Ca Sr, Ba), characterized in gas phase by mass spectrometry and vibrational spectroscopy. Group 3 elements form [Sc(CO)7]+ and [Y(CO)8]+ in gas phase. Group 7 elements as monocations resemble neutral group 6 derivative [M(CO)6]+ (M = Mn, Tc, Re). Group 8 elements as dications also resemble neutral group 6 derivatives [M(CO)6]2+ (M = Fe, Ru, Os).
== Routine Schedule of Immunization == Every Wednesday is designated as immunization day and is adopted in all parts of the country. Immunization is done monthly in barangay health stations, quarterly in remote areas of the country.
== The "no waste" culture == Sake kasu can be considered as a part of the "no waste" culture in Japan. Sake kasu is the waste produced by sake production, and the Japanese decided to use it because they do not want to waste any of the ingredients. A lot of sake kasu is produced during sake production and a lot of sake kasu is considered as industrial waste and being discarded. In order to reduce the waste produced by the sake kasu in Japan, it is recycled for use in other products. Some breweries sell their sake kasu directly to restaurants or put it into packages sold in convenient stores and supermarkets.
The Ayrshire and Simmental breeds were imported first, followed by the Brown Swiss, but few people wanted to crossbreed with them because of their large size, and the Japanese government encouraged it, but the crossbreds were very unpopular. The crossbreds' oversized stature made them inconvenient for Japan's narrow arable land, and their movements were slow and sluggish, and their temperaments were rough and lacking in obedience. They also had poor meat quality and were condemned from all quarters as being unsuitable for sukiyaki. As a result, from around 1907, there were no more crossbreds being bred, and in reaction, the old black cattle were considered good, and as long as they were small and black, they could be sold. As crossbreeding with Western breeds progressed, the term "pure Wagyu" (純粋和牛, junsui Wagyū) emerged to describe native Japanese cattle, and by 1912, it was claimed that there were two definitions of Wagyu: "pure Wagyu" and "improved Wagyu" (改良和牛, kairyō Wagyū). At that time, Mendel's laws had just been rediscovered, and both the Japanese government and cattle farmers lacked sufficient knowledge of genetics. The unpopularity of crossbred cattle led to the Japanese government's decision in 1911 to suspend plans to purchase Brown Swiss and Simmental cattle. In 1912, the Japanese government decided to formally end its policy of encouraging crossbreeding by announcing that crossbreeding between Wagyu and European breeds had been sufficiently successful. From then on, Wagyu improvement was based on pure Wagyu and improved Wagyu (crossbred cattle).
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.